skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin

Review

(2342) Views  (713) Full article downloads

Authors: Stanley S Schwartz

Published Date July 2010 Volume 2010:3 Pages 243 - 252
DOI: http://dx.doi.org/10.2147/DMSO.S6742

Stanley S Schwartz

Diabetes Disease Management at the University of Pennsylvania, Penn Presbyterian Medical Center, Philadelphia Heart Institute, Philadelphia, Pennsylvania, USA

Abstract: Insulin resistance and impaired beta-cell function are primary defects that occur early in the course of development of type 2 diabetes. Insulin resistance leads to hyperinsulinemia in order to maintain normal glucose tolerance. In most cases of type 2 diabetes, beta-cell dysfunction develops subsequent to the development of insulin resistance, and it is not until such beta-cell dysfunction develops that any abnormality in glucose tolerance is seen. Insulin resistance is a primary defect in type 2 diabetes. The risk of coronary heart disease is significantly increased in patients with type 2 diabetes. Cardiovascular disease causes 80% of all diabetic mortality, and in 75% of those cases, it is a result of coronary atherosclerosis. These points provide a rationale for early and aggressive management of cardiovascular risk in patients with diabetes. Thiazolidinediones represent an effective tool for targeting some features of this increased risk as they decrease insulin resistance and can prevent and/or delay diabetes progression.

Keywords: pioglitazone, type 2 diabetes, insulin






 

Other articles by Dr Stanley Schwartz



Readers of this article also read:
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio